← Home / INTELLIA THERAPEUTICS, INC. (NTLA)
Stock Analysis
INTELLIA THERAPEUTICS, INC. (NTLA)
NTLA
NTLA · Market data
11.09 +2.69%
Track NTLA in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when NTLA price is:
52W Range Position
15%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-07-31 11:46 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Weak / Negative
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
13.15
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
11
●
Financial Results
HIGH
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
(Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the first quarter ended March 31, 2026.
8-K Filing • SEC EDGAR
APR
30
●
Financial Results
HIGH
NTLA reports financial results
On April 28, 2026, Intellia Therapeutics, Inc.
8-K Filing • SEC EDGAR
What's Driving NTLA?
📈 Technical recovery is improving
Momentum is Neutral. Watch 13.15 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Downtrend Structure
Downtrend line not broken yet · score 0
Trigger
17.42
Invalidation
17.42
RSI(14)
35.2
◎
How to read this setup
From a roadmap perspective, the setup is boxed by support near 7.95 and resistance around 13.26. The chart still needs to reclaim resistance to improve meaningfully, while any loss of support would keep weakness in control.
Price Chart
NTLA — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-30
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$1.3B
Company size
EV
$1.2B
Debt-adjusted value
P/E
-3.4
Not meaningful
P/S
20.2
Very high
P/B
2.2
Balanced
EV/Sales
18.2
Premium
EV/EBIT
-2.9
Not meaningful
P/FCF
-3.7
Not meaningful
FCF Yield
-27.27%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Weak
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
15.05M
↘ Weak
📈 Net Income
-96.23M
↘ Negative
🧮 EPS (Basic)
-0.81
↘ Negative
INTELLIA THERAPEUTICS, INC.
Related Opportunities